Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
198 hedge funds and large institutions have $1.9B invested in Impax Laboratories, Inc. in 2016 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 92 increasing their positions, 56 reducing their positions, and 23 closing their positions.
490% more call options, than puts
Call options by funds: $20.7M | Put options by funds: $3.51M
64% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 56
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
2% more funds holding
Funds holding: 194 → 198 (+4)
9% less capital invested
Capital invested by funds: $2.09B → $1.9B (-$199M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Chicago,
Illinois
|
+$18.1M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.8M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$9.99M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$9.3M |
| 5 |
GAM
Gotham Asset Management
New York
|
+$8.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$29M |
| 2 |
AG
Aravt Global
New York
|
-$27.4M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$16.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9.95M |
| 5 |
Millennium Management
New York
|
-$9.1M |
IPXL Hedge Fund Activity: Q2 2016 in Review
198 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q2 2016, worth a combined $1.9B — down 9.5% from $2.09B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new IPXL positions and 23 closed out — a net gain of 5 holders — while 92 added to existing stakes and 56 trimmed.
The largest buyer was Mesirow Financial Investment Management - Fixed Income, opening a new position worth an estimated $18.1M. The largest seller was OrbiMed, cutting an estimated $29M.
- 198 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q2 2016, up from 194 in Q1 2016.
- Funds reported $1.9B of Impax Laboratories, Inc. stock for Q2 2016, down 9.5% quarter-over-quarter.
- 28 funds opened new Impax Laboratories, Inc. positions in Q2 2016 and 23 closed out, a net change of +5 holders.
- The largest Impax Laboratories, Inc. buyer in Q2 2016 was Mesirow Financial Investment Management - Fixed Income, an estimated $18.1M added.
- The largest Impax Laboratories, Inc. seller in Q2 2016 was OrbiMed, an estimated $29M sold.
Based on aggregated 13F filings for Q2 2016.